<DOC>
	<DOC>NCT00657709</DOC>
	<brief_summary>The proposed study was aimed to assess the immunogenicity, safety, tolerability and lot to lot consistency of 3 lots of Novartis Meningococcal B vaccine when given concomitantly with routine infant vaccines.</brief_summary>
	<brief_title>Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis, Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy 2month old infants (5589 days, inclusive) Prior vaccination with routine infant vaccines (Diphtheria, Tetanus, Pertussis, Polio, Haemophilus influenzae type b (Hib), and Pneumococcal antigens) Previous ascertained or suspected disease caused by N. meningitidis History of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component; Any serious chronic or progressive disease Known or suspected impairment or alteration of the immune system</criteria>
	<gender>All</gender>
	<minimum_age>55 Days</minimum_age>
	<maximum_age>89 Days</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>infant</keyword>
	<keyword>Meningococcal disease</keyword>
	<keyword>prevention</keyword>
	<keyword>vaccination</keyword>
</DOC>